Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138

Summary

RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells. PURPOSE: This clinical trial is to study genetically engineered lymphocyte therapy in treating patients with CD138 positive multiple myeloma that is relapsed (after stem cell transplantation or intensive chemotherapy) or refractory to further chemotherapy.

Timeline

Start

2013-06

Primary completion

2016-06

Completion

2016-06

Drugs

Indications